PMID- 27236591
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20181113
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 22
IP  - 4
DP  - 2016 Oct
TI  - Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric 
      Cancer: a Bayesian Network Meta-Analysis.
PG  - 853-61
LID - 10.1007/s12253-016-0078-1 [doi]
AB  - Fluoropyrimidine-based regimens are the most common treatments in advanced 
      gastric cancer. We used a Bayesian network meta-analysis to identify the optimal 
      fluoropyrimidine-based chemotherapy by comparing their relative efficacy and 
      safety. We systematically searched databases and extracted data from randomized 
      controlled trials, which compared fluoropyrimidine-based regimens as first-line 
      treatment in AGC. The main outcomes were overall survival (OS), progression-free 
      survival (PFS), overall response rate (ORR), and grade 3 or 4 adverse events 
      (AEs). A total of 12 RCTs of 4026 patients were included in our network 
      meta-analysis. Pooled analysis showed S-1 and capecitabine had a significant OS 
      benefit over 5-Fu, with hazard ratios of 0.90 (95%CI = 0.81-0.99) and 0.88 
      (95%CI = 0.80-0.96), respectively. The result also exhibited a trend that S-1 and 
      capecitabine prolonged PFS in contrast to 5-Fu, with hazard ratios of 0.84 
      (95%CI = 0.66-1.02) and 0.84 (95%CI = 0.65-1.03), respectively. Additionally, all 
      the three fluoropyrimidine-based regimens were similar in terms of ORR and grade 
      3 or 4 AEs. Compared with regimens based on 5-Fu, regimens based on S-1 or 
      capecitabine demonstrated a significant OS improvement without compromise of AEs 
      as first-line treatment in AGC in Asian population. S-1 and capecitabine can be 
      interchangeable according their different emphasis on AEs.
FAU - Zhu, Lucheng
AU  - Zhu L
AD  - Department of Oncology, Affiliated Hangzhou Hospital of Nanjing Medical 
      University, No.261, Huansha Road, Shangcheng District, Hangzhou, 310006, People's 
      Republic of China.
AD  - Department of Oncology, Hangzhou First People's Hospital, Hangzhou, 310006, 
      People's Republic of China.
FAU - Liu, Jihong
AU  - Liu J
AD  - Department of Oncology, Affiliated Hangzhou Hospital of Nanjing Medical 
      University, No.261, Huansha Road, Shangcheng District, Hangzhou, 310006, People's 
      Republic of China.
AD  - Department of Oncology, Hangzhou First People's Hospital, Hangzhou, 310006, 
      People's Republic of China.
FAU - Ma, Shenglin
AU  - Ma S
AD  - Department of Oncology, Affiliated Hangzhou Hospital of Nanjing Medical 
      University, No.261, Huansha Road, Shangcheng District, Hangzhou, 310006, People's 
      Republic of China. mashenglin@outlook.com.
AD  - Department of Oncology, Hangzhou First People's Hospital, Hangzhou, 310006, 
      People's Republic of China. mashenglin@outlook.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160528
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Drug Combinations)
RN  - 0 (Pyruvates)
RN  - 0 (fluoropyruvate)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bayes Theorem
MH  - Capecitabine/administration & dosage
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Middle Aged
MH  - Network Meta-Analysis
MH  - Oxonic Acid/administration & dosage
MH  - Pyruvates/administration & dosage
MH  - Stomach Neoplasms/*drug therapy
MH  - Tegafur/administration & dosage
OTO - NOTNLM
OT  - Advanced gastric cancer
OT  - Capecitabine
OT  - Fluoropyrimidine
OT  - Network meta-analysis
OT  - S-1
EDAT- 2016/05/30 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/05/30 06:00
PHST- 2015/03/01 00:00 [received]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2016/05/30 06:00 [entrez]
PHST- 2016/05/30 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
AID - 10.1007/s12253-016-0078-1 [pii]
AID - 10.1007/s12253-016-0078-1 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2016 Oct;22(4):853-61. doi: 10.1007/s12253-016-0078-1. Epub 
      2016 May 28.